S&P 500   4,286.64 (-0.30%)
DOW   33,476.52 (-0.56%)
QQQ   358.65 (+0.18%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.02 (+1.23%)
BABA   86.82 (+1.50%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.43 (-1.04%)
MU   68.20 (+4.60%)
CGC   0.79 (-3.49%)
GE   110.71 (-1.45%)
DIS   80.99 (+1.07%)
AMC   7.98 (+2.44%)
PFE   33.12 (+3.21%)
PYPL   58.40 (+0.38%)
NFLX   377.30 (+0.25%)
S&P 500   4,286.64 (-0.30%)
DOW   33,476.52 (-0.56%)
QQQ   358.65 (+0.18%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.02 (+1.23%)
BABA   86.82 (+1.50%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.43 (-1.04%)
MU   68.20 (+4.60%)
CGC   0.79 (-3.49%)
GE   110.71 (-1.45%)
DIS   80.99 (+1.07%)
AMC   7.98 (+2.44%)
PFE   33.12 (+3.21%)
PYPL   58.40 (+0.38%)
NFLX   377.30 (+0.25%)
S&P 500   4,286.64 (-0.30%)
DOW   33,476.52 (-0.56%)
QQQ   358.65 (+0.18%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.02 (+1.23%)
BABA   86.82 (+1.50%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.43 (-1.04%)
MU   68.20 (+4.60%)
CGC   0.79 (-3.49%)
GE   110.71 (-1.45%)
DIS   80.99 (+1.07%)
AMC   7.98 (+2.44%)
PFE   33.12 (+3.21%)
PYPL   58.40 (+0.38%)
NFLX   377.30 (+0.25%)
S&P 500   4,286.64 (-0.30%)
DOW   33,476.52 (-0.56%)
QQQ   358.65 (+0.18%)
AAPL   171.27 (+0.34%)
MSFT   316.07 (+0.77%)
META   301.19 (-0.91%)
GOOGL   130.96 (-1.02%)
AMZN   127.36 (+1.10%)
TSLA   249.95 (+1.45%)
NVDA   435.62 (+1.10%)
NIO   9.02 (+1.23%)
BABA   86.82 (+1.50%)
AMD   103.60 (+0.82%)
T   15.01 (+0.00%)
F   12.43 (-1.04%)
MU   68.20 (+4.60%)
CGC   0.79 (-3.49%)
GE   110.71 (-1.45%)
DIS   80.99 (+1.07%)
AMC   7.98 (+2.44%)
PFE   33.12 (+3.21%)
PYPL   58.40 (+0.38%)
NFLX   377.30 (+0.25%)
NYSE:CRL

Charles River Laboratories International (CRL) Stock Forecast, Price & News

$196.68
+1.37 (+0.70%)
(As of 03:21 PM ET)
Compare
Today's Range
$195.47
▼
$198.90
50-Day Range
$194.44
▼
$217.61
52-Week Range
$181.22
▼
$262.00
Volume
193,181 shs
Average Volume
521,912 shs
Market Capitalization
$10.08 billion
P/E Ratio
20.86
Dividend Yield
N/A
Price Target
$237.09
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Charles River Laboratories International MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
19.9% Upside
$237.09 Price Target
Short Interest
Healthy
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.02mentions of Charles River Laboratories International in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$1.72 M Sold Last Quarter
Proj. Earnings Growth
8.20%
From $10.49 to $11.35 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

64th out of 971 stocks

Commercial Physical Research Industry

3rd out of 14 stocks

See Top Rated MarketRank™ Stocks Here

CRL stock logo

About Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRL Price History

CRL Stock News Headlines

September 27, 2023 | finance.yahoo.com
Unveiling the Investment Potential of Charles River Laboratories International Inc (CRL): A ...
September 26, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and Immunovant (IMVT)
September 29, 2023 | Chaikin Analytics (Ad)
Legendary Stockpicker: "Buy this A.I. stock NOW"
His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock. MORE HERE...
September 26, 2023 | msn.com
Charles River (CRL) Opens a RightSource Lab in Stevenage
September 26, 2023 | finance.yahoo.com
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
September 26, 2023 | americanbankingnews.com
Charles River Laboratories International (NYSE:CRL) Price Target Cut to $209.00 by Analysts at TD Cowen
September 26, 2023 | americanbankingnews.com
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Moderate Buy" by Analysts
September 26, 2023 | americanbankingnews.com
Charles River Laboratories International, Inc. (NYSE:CRL) Receives $237.09 Consensus PT from Analysts
September 29, 2023 | Investor Place Media (Ad)
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
September 25, 2023 | nasdaq.com
TD Cowen Maintains Charles River Laboratories International (CRL) Market Perform Recommendation
September 25, 2023 | finance.yahoo.com
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
September 25, 2023 | americanbankingnews.com
William Blair Comments on Charles River Laboratories International, Inc.'s Q3 2023 Earnings (NYSE:CRL)
September 24, 2023 | americanbankingnews.com
Charles River Laboratories International (NYSE:CRL) Price Target Cut to $256.00
September 24, 2023 | americanbankingnews.com
Charles River Laboratories International (NYSE:CRL) Price Target Cut to $230.00
September 24, 2023 | americanbankingnews.com
Guggenheim Lowers Charles River Laboratories International (NYSE:CRL) Price Target to $225.00
September 24, 2023 | americanbankingnews.com
Charles River Laboratories International (NYSE:CRL) Price Target Cut to $275.00
September 22, 2023 | msn.com
Baird Maintains Charles River Laboratories International (CRL) Outperform Recommendation
September 22, 2023 | msn.com
Guggenheim Maintains Charles River Laboratories International (CRL) Buy Recommendation
September 22, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Charles River Labs (CRL)
September 22, 2023 | markets.businessinsider.com
Bank of America Securities Sticks to Their Buy Rating for Charles River Labs (CRL)
September 21, 2023 | msn.com
Charles River falls on Investor Day amid growth concerns
September 20, 2023 | americanbankingnews.com
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update
September 15, 2023 | finance.yahoo.com
Charles River (CRL) Announces Partnership With Related Sciences
September 6, 2023 | finance.yahoo.com
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods
August 30, 2023 | gurufocus.com
Unveiling Charles River Laboratories International's Value: Is It Really Priced Right? A ...
August 30, 2023 | finance.yahoo.com
Charles River Labs to shut 1 of 3 facilities in South San Francisco
August 25, 2023 | finance.yahoo.com
Charles River (CRL) Collaborates With Fondazione Telethon
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Company Calendar

Last Earnings
8/09/2023
Today
9/29/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:CRL
CUSIP
15986410
CIK
1100682
Web
www.criver.com
Phone
(781) 222-6000
Fax
978-988-5665
Employees
21,400
Year Founded
1947

Price Target and Rating

Average Stock Price Forecast
$237.09
High Stock Price Forecast
$275.00
Low Stock Price Forecast
$203.00
Forecasted Upside/Downside
+21.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$9.43
Trailing P/E Ratio
20.76
Forward P/E Ratio
18.67
P/E Growth
1.75
Net Income
$486.23 million
Net Margins
11.58%
Pretax Margin
15.02%
Return on Equity
18.99%
Return on Assets
7.47%

Debt

Debt-to-Equity Ratio
0.82
Current Ratio
1.49
Quick Ratio
1.21

Sales & Book Value

Annual Sales
$3.98 billion
Price / Sales
2.52
Cash Flow
$17.22 per share
Price / Cash Flow
11.37
Book Value
$58.47 per share
Price / Book
3.35

Miscellaneous

Outstanding Shares
51,270,000
Free Float
50,604,000
Market Cap
$10.04 billion
Optionable
Optionable
Beta
1.33

Social Links

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. James C. Foster J.D.Mr. James C. Foster J.D. (Age 72)
    Chairman, CEO & Pres
    Comp: $2.51M
  • Ms. Flavia H. Pease (Age 50)
    Corp. Exec. VP & CFO
    Comp: $772.4k
  • Ms. Birgit GirshickMs. Birgit Girshick (Age 53)
    Corp. Exec. VP & COO
    Comp: $1.15M
  • Mr. Joseph W. LaPlumeMr. Joseph W. LaPlume (Age 49)
    Corp. Exec. VP of Corp. Devel. & Strategy
    Comp: $871.35k
  • Mr. William D. BarboMr. William D. Barbo (Age 62)
    Chief Commercial Officer & Corp. Exec. VP
    Comp: $928.55k
  • Mr. Michael Gunnar KnellMr. Michael Gunnar Knell (Age 46)
    Corp. Sr. VP & Chief Accounting Officer
  • Prof. Julie Frearson Ph.D.
    Corp. Sr. VP & Chief Scientific Officer
  • Mr. Mark Mintz
    Corp. Sr. VP & Chief Information Officer
  • Todd Spencer
    Corp. VP of Investor Relations
  • Mr. Matthew L. Daniel
    Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CRL Stock - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRL shares.
View CRL analyst ratings or view top-rated stocks.

What is Charles River Laboratories International's stock price forecast for 2023?

11 equities research analysts have issued 1 year price objectives for Charles River Laboratories International's stock. Their CRL share price forecasts range from $203.00 to $275.00. On average, they predict the company's share price to reach $237.09 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts price targets for CRL or view top-rated stocks among Wall Street analysts.

How have CRL shares performed in 2023?

Charles River Laboratories International's stock was trading at $217.90 at the beginning of 2023. Since then, CRL shares have decreased by 10.1% and is now trading at $195.80.
View the best growth stocks for 2023 here.

Are investors shorting Charles River Laboratories International?

Charles River Laboratories International saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,700,000 shares, an increase of 10.4% from the August 31st total of 1,540,000 shares. Based on an average daily volume of 480,300 shares, the days-to-cover ratio is currently 3.5 days.
View Charles River Laboratories International's Short Interest.

When is Charles River Laboratories International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CRL earnings forecast.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings results on Wednesday, August, 9th. The medical research company reported $2.69 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.06. The medical research company earned $1.06 billion during the quarter, compared to analysts' expectations of $1.05 billion. Charles River Laboratories International had a net margin of 11.58% and a trailing twelve-month return on equity of 18.99%. The firm's quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.77 EPS.
Read the conference call transcript.

What ETFs hold Charles River Laboratories International's stock?

ETFs with the largest weight of Charles River Laboratories International (NYSE:CRL) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Future Fund Active ETF (FFND), Future Fund Long/Short ETF (FFLS), Horizon Kinetics Inflation Beneficiaries ETF (INFL), Franklin Genomic Advancements ETF (HELX), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of $10.30-$10.90 for the period, compared to the consensus estimate of $10.37. The company issued revenue guidance of $4.08 billion-$4.16 billion, compared to the consensus revenue estimate of $4.13 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $195.80.

How much money does Charles River Laboratories International make?

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $10.04 billion and generates $3.98 billion in revenue each year. The medical research company earns $486.23 million in net income (profit) each year or $9.43 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

The company employs 21,400 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?
The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More
How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.

This page (NYSE:CRL) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -